(Q45753081)

15 December 2017

title

Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine (English)

1 reference

15 December 2017

1 reference

Koike Y

1

1 reference

15 December 2017

Yoo YC

2

1 reference

15 December 2017

Mitobe M

3

1 reference

15 December 2017

Oka T

4

1 reference

15 December 2017

Okuma K

5

1 reference

15 December 2017

Tono-oka S

6

1 reference

15 December 2017

Azuma I

7

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

15 December 2017

published in

Vaccine

1 reference

15 December 2017

volume

16

1 reference

15 December 2017

issue

20

1 reference

15 December 2017

page(s)

1982-1989

1 reference

15 December 2017

Adjuvants--a balance between toxicity and adjuvanticity

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Adjuvanticity of mycobacterial cell walls

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Mitogenic activity of the cell walls of mycobacteria, nocardia, corynebacteria and anaerobic coryneforms

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Macrophage Dependency of T-lymphocyte Mitogenesis byNocardia rubraCell-Wall Skeleton

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Adjuvant activity of mycobacterial fractions. III. Adjuvant effect of cell wall of Mycobacterium bovis BCG on cell-mediated cytotoxicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Adjuvant activity of mycobacterial fractions. II. In vitro adjuvant activity of cell walls of mycobacteria, nocardia and corynebacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Does the cell wall skeleton from Bacille Calmette-Guérin directly induce interferon-gamma, independent of interleukin-12?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Studies on the virulence of tubercle bacilli; isolation and biological properties of a constituent of virulent organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

The chemical structure of the cord factor of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Natural and synthetic trehalose diesters as immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Lethal and adjuvant activities of cord factor (trehalose-6,6'-dimycolate) and synthetic analogs in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Adjuvants: current status, clinical perspectives and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

1 reference

7 January 2021

Immunoglobulin E-suppressing and immunoglobulin G-enhancing tetanus toxoid prepared by conjugation with pullulan

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Improvement of hepatitis B vaccine by the use of a new adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

Cytokine regulation of T-cell function: potential for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900084-X

7 January 2021

10.1016/S0264-410X(98)00084-X

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017